RxDoctor Payments Data

Evis Petrela, MD

Ophthalmology · Syracuse, NYNPI 1225200900

Payments from drug & device makers

$6,013in general payments, 2019–2025

Across 202 payments — averaging $29.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Microsurgical Technology, Inc.$977
  • Sight Sciences, Inc.$634
  • AbbVie$567
  • Glaukos Corporation$273
  • Bausch & Lomb Americas Inc.$176
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$5,03684%
  • Charitable contribution$97716%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,013 in reported general payments places this provider in the 80th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$413,938
Medicare patients
1,359
Services billed
3,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine52$74,464
RocklatanNetarsudil Mesylat/Latanoprost87$51,779
LumiganBimatoprost67$40,205
XiidraLifitegrast14$21,486
Prednisolone Acetate649$20,278
VyzultaLatanoprostene Bunod33$20,192
Cyclosporine24$19,233
CombiganBrimonidine Tartrate/Timolol41$18,734
Brimonidine Tartrate204$16,309
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol111$16,027
Loteprednol Etabonate112$13,288
Latanoprost1,207$12,541
Dorzolamide-TimololDorzolamide/Timolol/Pf78$11,292
Timolol Maleate261$7,856
LotemaxLoteprednol Etabonate20$7,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$567$133,402160 claims
Aerie Pharmaceuticals, Inc.Rocklatan$13$51,77987 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$176$41,67847 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax$116$20,299132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →